Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients

The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017...

Full description

Bibliographic Details
Main Author:	Alexey A. Larionov
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-04-01
Series:	Frontiers in Oncology
Subjects:	HER2 metastatic breast cancer trastuzumab pertuzumab lapatinib trastuzumab-emtansine
Online Access:	http://journal.frontiersin.org/article/10.3389/fonc.2018.00089/full

Similar Items

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
by: Michela Donadio
Published: (2018-06-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
by: Thibaut Sanglier, et al.
Published: (2022-05-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
by: Maria Moritti, et al.
Published: (2018-06-01)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
by: Thibaut Sanglier, et al.
Published: (2023-06-01)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
by: Sanne L. de Haas, et al.
Published: (2023-01-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER
by: D. D. Sakaeva
Published: (2017-11-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

Long-term survival in a young woman with recurrent HER2-positive breast cancer.
by: Gianluca Cotroneo
Published: (2018-06-01)

Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
by: E V Artamonova, et al.
Published: (2015-06-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
by: Eyyup Cavdar, et al.
Published: (2022-08-01)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
by: Michael P. Lux, et al.
Published: (2018-12-01)

Personalized approach to HER2-positive advanced breast cancertherapy
by: M B Stenina
Published: (2014-09-01)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
by: Luai S. Al Rabadi, et al.
Published: (2021-10-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
by: William Jacot, et al.
Published: (2019-11-01)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
by: Fangfang Duan, et al.
Published: (2022-03-01)

Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2
by: Claudio Vernieri, et al.
Published: (2017-12-01)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
by: Jeffrey V. Leyton
Published: (2020-07-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

HER2‐positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab‐based chemotherapy: A case report
by: Raffaele Longo, et al.
Published: (2020-12-01)

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
by: Mark Barok, et al.
Published: (2018-05-01)

Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial
by: Nianhua Ding, et al.
Published: (2024-01-01)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
by: Elena López-Miranda, et al.
Published: (2020-11-01)

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer
by: M Basade, et al.
Published: (2018-01-01)

Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series
by: Edy Ippolito, et al.
Published: (2022-01-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
by: Kreina Sharela Vega Cano, et al.
Published: (2022-12-01)